Modern Rheumatology

, Volume 22, Issue 3, pp 370–375

Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice

Authors

    • Department of Orthopedic Surgery and Rheumatology, Nagoya University HospitalNagoya University, School of Medicine
  • Atsushi Kaneko
    • Department of Orthopedic SurgeryNagoya Medical Center
  • Yuji Hirano
    • Department of RheumatologyToyohashi Municipal Hospital
  • Hisato Ishikawa
    • Department of RheumatologyNagano Red Cross Hospital
  • Hiroyuki Miyake
    • Department of Orthopedic SurgeryIchinomiya Municipal Hospital
  • Hideki Takagi
    • Department of Orthopedic SurgeryNagoya Kyoritsu Hospital
  • Yuichiro Yabe
    • Department of RheumatologyTokyo Kosei Nenkin Hospital
  • Takefumi Kato
    • Kato Orthopedic Clinic
  • Kenya Terabe
    • Department of Orthopedic SurgeryFukuroi Municipal Hospital
  • Naoki Fukaya
    • Department of Orthopedic SurgeryKariya-Toyota General Hospital
  • Hiroki Tsuchiya
    • Department of Orthopedic SurgeryNagoya Kyoritsu Hospital
  • Tomone Shioura
    • Department of Orthopedic SurgeryShizuoka Kosei Hospital
  • Koji Funahashi
    • Department of Orthopedic Surgery and Rheumatology, Nagoya University HospitalNagoya University, School of Medicine
  • Masatoshi Hayashi
    • Department of Orthopedic Surgery and Rheumatology, Nagoya University HospitalNagoya University, School of Medicine
  • Daizo Kato
    • Department of Orthopedic Surgery and Rheumatology, Nagoya University HospitalNagoya University, School of Medicine
  • Hiroyuki Matsubara
    • Department of Orthopedic Surgery and Rheumatology, Nagoya University HospitalNagoya University, School of Medicine
  • Naoki Ishiguro
    • Department of Orthopedic Surgery and Rheumatology, Nagoya University HospitalNagoya University, School of Medicine
    • Department of Orthopedic Surgery, Faculty and Graduate School of MedicineNagoya University
Original Article

DOI: 10.1007/s10165-011-0528-2

Cite this article as:
Kojima, T., Kaneko, A., Hirano, Y. et al. Mod Rheumatol (2012) 22: 370. doi:10.1007/s10165-011-0528-2

Abstract

The goal of treating rheumatoid arthritis (RA) should be remission, for which a new definition was proposed in 2011. To determine which patients can achieve the new Boolean-based definition of remission in clinical practice, we analyzed factors associated with remission in 123 patients who received tocilizumab for 52 weeks. We found that patients with short disease duration (<4.8 years) had a significantly higher rate of remission (31.7%) than those with longer disease duration, and patient global assessment was the most important factor for achieving remission. Multivariate analysis revealed the following predictors of remission: short disease duration [<4.8 years; odds ratio (OR) 2.5, 95% confidence interval (CI) 1.4–4.7] and lower disease activity [28-joint disease activity score–erythrocyte sedimentation rate (DAS28-ESR) <5.23; OR 2.5, 95% CI 1.2–5.1). In this study, we showed that remission, as newly defined using a Boolean approach, is a realistic goal for patients treated with tocilizumab with short disease duration in real-world clinical practice.

Keywords

Rheumatoid arthritis Remission Tocilizumab Patient-reported outcome Interleukin 6

Copyright information

© Japan College of Rheumatology 2011